184 related articles for article (PubMed ID: 34402192)
1. Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.
Salans M; Courtney PT; Yip A; Murphy JD
Cancer Med; 2021 Oct; 10(19):6618-6626. PubMed ID: 34402192
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
[TBL] [Abstract][Full Text] [Related]
4. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
Freeman M; Betts KA; Jiang S; Du EX; Gupte-Singh K; Lu Y; Rao S; Shoushtari AN
Adv Ther; 2019 Oct; 36(10):2783-2796. PubMed ID: 31440980
[TBL] [Abstract][Full Text] [Related]
5. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK
Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153
[TBL] [Abstract][Full Text] [Related]
7. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.
Li M; Basu A; Bennette C; Veenstra D; Garrison LP
Value Health; 2019 Jul; 22(7):777-784. PubMed ID: 31277824
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of adjuvant interferon in node-positive melanoma.
Cormier JN; Xing Y; Ding M; Cantor SB; Salter KJ; Lee JE; Mansfield PF; Gershenwald JE; Ross MI
J Clin Oncol; 2007 Jun; 25(17):2442-8. PubMed ID: 17557957
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
[TBL] [Abstract][Full Text] [Related]
10. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
11. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
12. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
14. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
[TBL] [Abstract][Full Text] [Related]
17. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.
Ye ZM; Tang ZQ; Xu Z; Zhou Q; Li H
Front Public Health; 2022; 10():947375. PubMed ID: 35937220
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC.
Li J; Zhang T; Xu Y; Lu P; Zhu J; Liang W; Jiang J
Immunotherapy; 2020 Oct; 12(14):1067-1075. PubMed ID: 32811247
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
[Next] [New Search]
